We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Zincum metallicum 5cH increases survival and improves clinical mice infected with Trypanosoma cruzi.
- Authors
Ciupa, Larissa; da Veiga, Franciele Karina; Portocarrero, Angela Rigo; Sandri, Patricia Flora; Ferraz, Fabiana Nabarro; Ferreira, Érika Cristina; Lopes Lera, Katiucha Rebeca Jennifer; Holandino, Carla; Aleixo, Denise Lessa; de Araújo, Silvana Marques
- Abstract
The Multicenter International Project suggests Zincum mettalicum high diluted as an object of study in different experimental models. Aim: evaluate the effect of substance high diluted Zincum metallicum in murine experimental infection by Trypanosoma cruzi. Metodology: was performed a blind, controlled, randomized, using 60 swiss male mice, 56 days old, divided into groups: CNI - uninfected and untreated animals; CI - infected and untreated animals; infected and treated animals: ZN5cHTA - Zinc 5ch and LAC5cHTA - Lactose 5ch , 48 hours before and after infection, subsequently were treated 56/56 hours until 9th day of infection; ZN5cHTTD - Zinc 5Ch and LAC5cHTTD - Lactose 5CH everyday from the 4th of infection. Animals were inoculated with 1.400 blood trypomastigotes, strain Y-T. cruzi, intraperitoneally. Medicines were handled according to the Brazilian Homeopathic Pharmacopoeia[1], on separate days (first Lactose and then Zinc) and stored in different rooms. Microbiological testing (RDC n° 67MS-Brazil), in vivo biological test and toxicity test was performed. Treatment was diluted in water (1mL/100mL). Clinical (temperature, weight, water/foodintake and excreta)[2] and parasitological parameters (pre-patent and patent period, peak parasitemia, and parasitemia overall survival time)[3] were assessed daily. Data were compared BioEstat 5.0, significance level of 5 %. Results: ZN5cHTA group had a higher survival time than their control LAC5cHTA (p=0.004). ZN5cHTA shows 55.7% probability of surviving to the 15th day after infection, while LAC5cHTA 29.4%. ZN5cHTA also provides significantly better performance (p= 0.0206) compared to CI, contrary to what occurs with LAC5cHTA x CI (p=0.7410), showing once again the superiority of action ZN5cHTA. There is no significant difference in survival between the different treatments schemes TA and TTD, either with ZN5cH (p=0.0754) or LAC5cHTA (p=0.9480), although ZN5cHTA present the best trend toward benefit. Considering parasitological parameters ZN5cHTA group had higher pre-patent period (PPP) meaning benefit to infected animals [4]. Although ZN5cHTA present greater number of parasites in relation to LAC5cHTA (p = 0.020) considering the 6-11th day of infection period, showing a better performance compared to the other groups as observed in other models [5]. Conclusion: ZN5cHTA group had higher survival, greater pre-patent period and better clinical outcome compared to its LAC5cHTA control and the other groups although it had higher total parasitemia, the posterior control of infection might be related to the increase of parasitemia in a previous period.
- Subjects
TRYPANOSOMA; MEDICAL prescriptions; MOLECULAR immunology; IMMUNOMODULATORS; BIOTHERAPY; DILUTION; PHYSIOLOGY
- Publication
International Journal of High Dilution Resarch, 2014, Vol 13, Issue 47, p111
- ISSN
1982-6206
- Publication type
Article